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Pathophysiology and symptomatology of chronic
heart failure
Chronic heart failure (CHF) is a condition char-
acterized by heart insufficiency in adequate blood
supplying, delivering to peripheral tissues. The main
hemodynamic pathomechanism of CHF is associated
with progressive decrease of the cardiac output, aris-
ing from impairment heart function as a pump in car-
diovascular system (systolic heart failure). Diastolic
ventricular dysfunction results in intravascular and
interstitial volume overload, which also leads to
lower cardiac end diastolic volume and, in conse-
quence, lower cardiac output ñ to poor tissue perfu-
sion. Clinically, taking into consideration the course
of the disease and predominance symptoms, heart
failure is divided into acute and chronic one and into
right ventricle, left one or both ventricles cardiac
insufficiency. The CHF incidence increases with
age. About 1% of patients older than 50 years expe-
rience heart failure, but in people aging at least 80,
10% of CHF prevalence is observed with the 40% of
isolated systolic and both 30% of diastolic and 30%
of mixed chronic heart failure occurrence (1ñ3). 
The CHF symptomatology is complex, focused
on both peripheral and pulmonary venous conges-
tion and decreased effective arterial blood volume
(EABV) ñ tissue perfusion. Thus, main CHF symp-
toms arise from venous blood accumulation before
heart: peripheral and pulmonary interstitial edemas
(secondary to volume overload), dyspnea and non-
productive cough (caused by pulmonary conges-
tion), orthopnea (resulting from blood redistribution
from the legs to the central circulation when patient
lies down at night), jugular veins enlargement and
hepatosplenomegaly. The symptoms originated
from decreased cardiac output are also observed:
fatigue (associated with reduced blood oxygena-
tion), intolerance of physical activity (inability to
increase cardiac output), restlessness and confusion.
Chronic heart failure is a common end way of all
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heart diseases. It can be a result of both volume
(e.g., in aortic or pulmonary valve insufficiencies,
congestive cardiomiopathy, congenital heart dis-
ease) or pressure overload (in hypertension, aortic or
pulmonary valve stenosis, hypertrophic cardiomy-
opathy, chronic obstructive pulmonary disease),
restricted filling of the heart (mitral or tricuspid
valve stenosis, constrictive pericarditis) or
decreased cardiomyocyte contractility (coronary
artery disease, connective tissue disease, poisons
and drugs: alcohol, cobalt, antineoplastic drugs,
especially antracyclines) (1ñ3).
Heart dysfunction caused by any factors men-
tioned above, results in its progressive worsening
which triggers compensatory mechanisms activation.
Initially, both the sympathetic and renin-angiotensin-
aldosterone system (RAAS) activity provides back-
ground to restore cardiac output and peripheral perfu-
sion of vital organs. However, long-term sympathetic
stimulation, together with RAAS activation lead to
increased preload (due to venous vasoconstriction,
increased venous return, augmented by water and sodi-
um renal retention) and afterload (due to increased
arterial peripheral resistance), which aggravate heart
insufficiency symptoms. Moreover, two powerful
vasoconstrictory peptides are secreted ñ vasopressin
(AVP) from posterior pituitary gland and endothelin
(ET) from endothelial cells. These peptides, together
with aldosterone, are co-responsible for cardiac remod-
elling and deposition of collagen in the interstitial
matrix. Additionally, AVP augments renal reabsorp-
tion of water. In CHF, natriuretic peptides system is
also engaged to counteract initially the cardio- and
vasopressive effects mentioned above. However, this
compensatory mechanism is not effective to prevent
from further progress of the chronic heart disease. CHF
is also associated with cytokines secretion, released
from various immunoreactive cells in response to
injury. In CHF patients, TNF-α and Il-1 plasma levels
are increased. They appear to play an important role in
myocyte hypertrophy and apoptosis (3, 4).
Summing up, neuroendocrine activation plays
a key role in CHF pathogenesis and it seems to be
attractive target of pharmacological interventions.
The purpose of this mini review is to shortly
describe current and possible therapeutic perspec-
tives, based on the influence into neuroendocrine,
compensatory mechanisms, activated in CHF. They
are summarized in Table 1. 
The renin-angiotensin-aldosterone system
(RAAS) and sympathetic nervous system
Currently administrated drugs, effective in
CHF treatment, may be distinguished in RAAS inhi-
bition, β-blockers, diuretics or agents which dimin-
ish vascular resistance (such as hydralazine and
nitrates, dihydropyridine and nondihydropyridine
calcium channels blockers). 
The renin-angiotensin-aldosterone system
(RAAS) and sympathetic nervous system (SNS)
play important role in pathogenesis of CHF, being
the most important compensatory mechanisms, trig-
gering in CHF development. Physiologically,
RAAS and SNS are responsible for cardiac and
vasomotor activity (causing an increase in total
peripheral resistance and mean blood pressure),
renal intracapillary pressure, glomerular filtration
rate, maintain optimal salt and water homeostasis
and control of tissue growth. These systems are
greatly activated in CHF in response to threats that
compromise blood pressure stability and extracellu-
lar fluid volume homeostasis, such as decrease of
effective artery blood volume (in CHF) and in many
other unstable hemodynamic conditions (5, 6). 
The key element of RAAS system ñ
angiotensin II (AII) mediates its effects by two kinds
of receptors ñ AT1 and AT2. AT1 receptors are dis-
tributed in the blood vessels, kidney, heart, liver and
brain whereas AT2 ones ñ in the adrenal medulla,
uterus, ovary, blood vessels and certain brain
regions. Activation of AT1 leads to the systemic and
renal vasoconstriction, increased renal sodium reab-
sorption, vascular smooth muscle growth, oxidative
stress and inflammatory cytokines activation,
endothelial dysfunction and increased plasminogen
activator inhibitor 1 activity. On the contrary, bio-
logical effects mediated via AT2 stimulation
include: systemic and renal vasodilatation,
decreased renal sodium reabsorption, decreased
inflammation and myocyte hypertrophy with car-
diac muscles fibrosis. Moreover, activation of AT1
receptors in zona glomerulosa of the supraadrenal
glands stimulates the aldosterone secretion.
Aldosterone is a mineralocorticoid, which acts via
receptors expressed in the kidneys and results in
sodium and water retention (thus, it plays an essen-
tial role in blood pressure and volume regulation). It
is not only under control of AII, but its secretion is
also mediated by other factors, such as hyponatrem-
ia, hyperkalemia and hypovolemia. Moreover,
recently it has been shown that aldosterone receptors
are found in other tissues including heart, brain and
blood vessels and contribute to their fibrosis and
remodelling (together with angiotensin) (5, 6).
Overexpression of RAAS together with
increased SNS activity observed in CHF contribute
to further CHF development, hypertension and relat-
ed target-organ damage. The impact of RAAS on
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kidneys manifests by its effects on intravascular vol-
ume and blood pressure regulation. The raise of
blood pressure after both RAAS and sympathetic
stimulation results in direct vasoconstriction of the
systemic vessels. Upon activation of AT1 receptors
of the efferent arteriole and its contraction, AII
reduces the renal blood flow and increases the
glomerulal filtration and proximal sodium and fluid
reabsorption. Additionally, aldosterone has its major
effect in distal nephron sodium reabsorption through
the epithelial sodium channel. The renal AT1 recep-
tor activation promotes collagen deposition (through
reduction in protein degradation by inhibition of
proteases), inflammatory process by production of
the inflammatory factors (TGF-β, PDGF, and
nuclear factor κB synthesis) and fibroblasts activa-
tion. These effects lead to enhanced progressive
renal injury from glomerulosclerosis and tubuloint-
erstitial fibrosis. The similar consequences of acti-
vated RAAS are observed in heart, including:
myocyte hypertrophy with left ventricular hypertro-
phy, fibrosis, increased expression of matrix metal-
loproteinase and augmented oxidative stress. These
disturbances predispose to heart failure through the
diminished contractility and/or abnormal diastolic
filling as well as cardiac rhythm perturbations.
Moreover, RAAS is responsible for vasoconstric-
tive, hypertrophic, atherosclerotic, inflammatory
and prothrombotic effects in coronary arteries. The
systemic blood pressure elevates through total
peripheral resistance increase, vascular smooth mus-
cles remodelling and endocrine and metabolic
endothelial disturbances (especially depletion in
endothelial nitric oxide secretion, sympathetic activ-
ity enhancement and augmented response to vaso-
constrictor substances) (7ñ9). 
Thus, suppressing RAAS and SNS are the most
important pharmacological targets in treatment of
the CHF. Agents acting via this mechanism are
regarded to be of essential meaning in present CHF
pharmacotherapy. The guidelines recommend selec-
tive β1 antagonists administration (in appropriate
doses; adequate to prevent from late organ damage
but not exacerbating the heart insufficiency) (10,
11). Currently used RAAS inhibitory drugs include:
angiotensin converting enzyme inhibitors (ACEI),
angiotensin receptor blockers (ARB) and aldos-
terone antagonists (spironolactone, eplerenone)
(12). Moreover, now there is an additional possibil-
ity of RAAS inhibition, using renin inhibitors
(ìskirensî, e.g., aliskiren) and a new class of com-
bined ACE and neutral endopeptidase (NEP)
inhibitors ñ vasopeptidase inhibitors (VPI) (see
below). 
Summing up, general agreement exists that RAAS
and SNS inhibition in heart failure provides benefi-
cial effects: normalization of elevated blood pres-
sure, regression of ventricular hypertrophy, inhibi-
tion of vascular smooth muscle growth, stabilization
of renal function and improvement in proteinuria
(especially in diabetic patients), reduction in activa-
tion of sympathetic nervous system, normalization
of endothelial behavior and enhancement of fibri-
nolytic activity (13ñ17). Agents inhibiting RAAS
and SNS activity are regarded to be the most impor-
tant pharmacological intervention in CHF pharma-
cotherapy. The further part of this mini-review will
be focused on the other new neuroendocrine
changes, which also seem to be interesting pharma-
cological targets. 
Vasopressin. Vasopressin receptor antagonists
(VRA) ñ vaptans
The next essential factor playing role in CHF
pathophysiology is vasopressin (AVP) ñ antidiuret-
ic hormone (ADH), which is produced by neurose-
cretory hypothalamic periventricular and supraoptic
nuclei. AVP is then released from posterior pituitary
in response to hyperosmolality and hypovolemia. It
is responsible for augmented water reabsorption in
distal renal tubules and for blood vessel contraction.
These effects are mediated by AVP interacting with
membrane receptors V1, V2, located in distal organs
(18, 19).
The AVP increase is observed in CHF, being a
result of effective arterial blood volume decrease,
diminished renal blood flow and baroreceptors stim-
ulation, which result in compensatory vasopressin
secretion (and other neuroendocrine activation,
including RAAS and SNS). Hyponatremia extends
as a result of disturbed sodium balance, secondary to
hyperaldosteronism development and vasopressin
overproduction. These hormones favor CHF pro-
gression, causing an increase in total peripheral
resistance and contributing to adverse heart remod-
elling in long-term survival perspective (20). 
Thus, pharmacological concept of VRA, the
so-called ìvaptansî or ìaquareticsî administration
in CHF treatment has been introduced. Taking into
consideration pathophysiological implications, there
are possibilities of selective or non-selective vaso-
pressin receptors antagonism. However, the benefi-
cial hemodynamic effects observed after selective
V1A receptor antagonists (vasodilatation,
antiplatelet) are partly abolished by an increase of
water reabsorption arising from coexistence of renal
V2 receptor stimulation. Thus, there is no back-
ground to administrate selective V1A VRA in CHF. 
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Table 2. Selected new agents studied in CHF (and other cardiovascular entities) treatment (23, 31, 44)
International Pharmacological Confirmed or suggested
name Trade name action; according to clinical
INN Name (if was given) Receptor selectivity studies indication for use  
VASOPRESSIN RECEPTOR ANTAGONISTS (VRA)




Lixivaptan óó- V2 antagonist Hypervolemic 
hyponatremia in CHF
Euvolemic hyponatremia 
in SIADH  
Satavaptan AQUILDA V2 antagonist Euvolemic 
hyponatremia in CHF
Ascites in liver 
cirrhosis
Mozavaptan PHYSULINE weak V1A Euvolemic
antagonist hyponatremia
strong V2 in SIADH
antagonist
Conivaptan VAPRISOL weak V1A Hypervolemic 
antagonist hyponatremia in CHF
strong V2 Euvolemic 
antagonist hyponatremia in 
SIADH
Relcovaptan óó- V1A antagonist Preterm labour
Dysmenorrhoea
Reynolds disease  
NATRIURETIC PEPTIDES
NEUTRAL ENDOPEPTIDASE INHIBITORS (NEPI)
VASOPEPTIDASE INHIBITORS (VPI)
recombinant BNP NESIRITIDE NPR-A agonist CHF, Coronary artery
NATRECOR disease, Pulmonary 
hypertension
Sampatrilat óó 
Gemopatrilat óó NEP inhibition CHF
Fasidotril óó ACE inhibition Hypertension
Omapatrilat VANLEV    
ENDOTHELIN RECEPTOR ANTAGONISTS (ERA)
Ambrisentan LETAIRIS (USA) ETA/ETB dual Pulmonary 
VOLIBRIS (EU) antagonist hypertension
Atrasentan XINLAY (USA) ETA antagonist Prostate cancer
Bosentan TRACLEER (EU) ETA/ETB dual CHF, Pulmonary 
antagonist hypertension
Clazosentan PIVLAZ ETA antagonist Subarachnoid 
hemorrhagia
Darusentan ó- ETA antagonist Coronary artery disease
Hypertension  
Tezosentan VELETRI ETA/ETB dual Acute Heart Failure
antagonist Pulmonary hypertension
Sitaxsentan THELIN (EU) ETA antagonist CHF Pulmonary 
hypertension  
TNF-α ANTAGONISTS
Recombinant human TNF-α receptor ETANERCEPT TNF-α CHF
Anti TNF-α monoclonal antibody INFLIXIMAB TNF-α CHF
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Similarly, it might be expected that selective
antagonism of renal V2 receptor, causing the
aquaretic effect is accompanied by V1 unoccupied
receptors activation, leading to an increase of vascu-
lar resistance. The rational conclusion of limitations
mentioned above is a usage of double V1A/V2
antagonists. On the other hand, studies focused on
selective V2 vaptans in CHF treatment have not
revealed exacerbation of this clinical entity so far. It
seems possible, that pressive responses resulting
from unoccupied V1A receptors stimulation are not
strong enough to outnumber the antagonistic effect
of VRA on renal V2 receptors. 
It is believed that VRA, causing an abolition of
water reabsorption in distal renal tubules and induc-
ing increased urine excretion (aquaretic effect) lead
to hemodynamic improvement in CHF, which is
secondary to preload decrease. Thus, in clinical
practice, selective V2 receptor antagonists (aquaret-
ic effect) and non-selective V1A/V2 ones (aquaresis
with peripheral vasodilatation) have essential patho-
physiological meaning (18, 19, 21ñ23). The exam-
ples of selected VRA are given in Table 2. 
Natriuretic peptides. Neutral endopeptidase and
vasopeptidase inhibitors
The next important element of compensatory
response, developing in chronic CHF, includes an
increase in natriuretic peptides levels. The family of
these compounds is composed of: atrial natriuretic
peptide (ANP), brain natriuretic peptide (BNP) and
C-natriuretic peptide (CNP). Both ANP and BNP
are synthesized mainly in response to increased left
ventricle end diastolic pressure and intra-arterial
pressure loads. The other factors involved in
ANP/BNP release are: endothelin, angiotensin II
and cytokines such as: TGF-β, Il-1, LPS, FGF
(24ñ26). 
Natriuretic peptides modulate cardiovascular
functions via natriuretic peptide receptor (NPR)-A
and NPR-B, causing systemic vasodilatation, RAAS
and sympathetic nervous system inhibition. They
also cause afferent glomerular arterioles dilatation
together with efferent ones contraction, leading to
diuresis enlargement. ANP/BNP also diminish sodi-
um reabsorption in renal tubules causing natriuresis.
Additionally, they increase vascular permeability
and intravascular fluid shift into extravascular
space, which augment hypotensive effect caused by
vasodilatation and natriuresis. ANP/BNP also
diminishes vascular smooth muscles proliferation
and cardiomyocytes remodelling (24).
Natriuretic peptides released in CHF are
responsible for beneficial compensatory effects,
contributing to decrease of both preload and after-
load. Many studies revealed proportional relation-
ship between increased natriuretic peptides level and
intensification of both systolic and diastolic CHF
symptoms. At present, ANP/BNP measurement
becomes a valuable diagnostic tool, especially in
case of oligosymptomatic patients in early CHF
stage. Assay of natriuretic peptides level also creates
possibility of estimation of CHF pharmacotherapy
efficacy (effective treatment results in a decrease of
plasma natriuretic peptides level) (25ñ28). 
The predominant directions in searching for
agents influencing natriuretic peptides system are
inhibitors of ANP/BNP enzymatic breakdown. Two
classes of them are distinguished: neutral endopepti-
dase inhibitors (NEPI) and vasopeptidases inhibitors
(VPI) ñ enzymes responsible for various biological
peptides degradation, including ANP and BNP (24,
26). Neutral endopeptidase (neprilysin) is an
enzyme found especially in renal tubules and
nephrons. In several clinical studies, administration
of candoxartil ñ one of NEPI, increased natiuresis
and diuresis. Despite these effects, suggesting the
ANP increase after candoxartil, no significant
reduction of blood pressure was noted, both in
hypertensive and normotensive participants. The
reason of the limited hypotensive efficacy of NEP
inhibitors may be associated with small enzymatic
selectivity of these agents. Beside ANP/BNP, NEP
is an additional pathway of many other peptides
degradation, including vasopressive ones such as
angiotensin or endothelin. NEP blockade accom-
plished by candoxartil and analogues leads to simul-
taneous plasma level increase of both natriuretic
peptides and vasoconstrictory factors as well. These
changes cause an opposite impact on blood pressure
regulatory mechanisms, without finally expected
hypotensive effect. Despite a lack of the afterload
decrease, NEP inhibitors are reported to be benefi-
cial in CHF treatment, especially because of lower-
ing the preload, secondary to natriuresis with no
direct impact on RAAS and sympathetic activity.
Hypothetically, in a close future, NEP inhibitors
may be considered as an alternative for ìclassicalî
diuretics, commonly administrated in CHF patients
(24, 26, 29). 
A lack of NEP selectivity and pharmacological
contrary effects after NEP inhibitors (simultaneous
increase cardio- and vasopressive peptides together
with natriuretic peptides) brought up interest on
agents blocking of two enzymes ñ neutral endopep-
tidase and angiotensin converting enzyme (ACE).
New, unique compounds were discovered called
vasopeptidase inhibitors ñ VPI. They combine dou-
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ble activity ñ simultaneous NEP inhibition (as clas-
sic NEP inhibitors) with ACE blockade (as ACE
inhibitors). 
According to VPI pharmacodynamic proper-
ties, combination of dual enzymatic blockade leads
to an increase of natriuretic peptides with no accom-
panying increase of angiotensin II and aldosterone.
Moreover, an elevation of kinin level is indirectly
observed, also secondary effect of ACE inhibition. It
is regarded that beneficial hemodynamic effects
elicited by VPI result not only from direct impact on
ANP/BNP and RAAS, but also from kinins overac-
tivity. Bradykinin is broken down by both NEP and
ACE, thus VPI administration causes considerable
augmentation of kinins action. It is associated with
subsequent nitric oxide (endothelial derived relax-
ing factor) and prostacyclin increase. Thus, it seems
that VPI also show antiplatelet effects and improve
dysfunction of the blood rheology. It was also found
that VPI caused adrenomedullin increase, however,
it is not explained if this peptide has significant role
in VPI renal action (26, 29ñ31). 
The important limitations of VPI introduction
into general practice are their possible side effects.
VPI administration was associated with various
adverse effects: dizziness, headache, nausea. Dry
cough was also a significant VPI adverse effect,
similarly to ACE inhibitors. However, the most
important unpleasant side effect was angioedema.
This phenomenon is also observed in 0.1ñ0.5%
patients receiving ACE inhibitors. The daily admin-
istrated omapatrilat (in a dose of 20 mg), generated
angioedema about three times more often than ACE.
It is not known, if other VPI cause this harmful
effect with such frequency (32). The examples of
currently studied NEPI and VPI are presented in
Table 2.
Endothelin. Endothelin receptor antagonists
(ERA) 
Endothelin-1 (ET-1) is a 21-amino acids pep-
tide which is found to possess 10-times stronger
vasoconstrictory and pressive properties than
angiotensin II. ET-1 is secreted under the influence
of various growth factors and cytokines, such as:
thrombin, TGF-β, TNF-α, insulin, free oxygen rad-
icals, catecholamines, angiotensin II, vasopressin
and hypoxia, and as a response to increased mechan-
ical stimuli, such as shear stress. ET-1 synthesis is
inhibited by nitric oxide, natriuretic peptides,
heparin and prostaglandins. The main sources of
ET-1 are vascular endothelium, cardiomyocytes,
vascular smooth muscles, renal tubules, nephron
mesangium, pituitary gland, liver and lungs, which
implicates that this peptide plays important regula-
tory functions in various organs (33, 34). 
Endothelin acts via membrane receptors,
labelled as ETA and ETB. ETA receptor is located
mostly on vascular smooth muscle cells (VSMC),
whereas ETB on both VSMC and endothelium.
Initially it was suspected that ETA VSMC receptor
stimulation causes vasoconstriction while endothe-
lial ETB ñ vasodilatation. At present, it was proved
that both ETA and ETB receptors are situated on
VSMC and they induce coronary, renal, portal and
intestinal vasoconstriction. Thus, finally strong con-
tracting and proliferative ET-1 effect is a result of
ETA/ETB VSMC receptors activation, only partly
abolished by the influence of ET-1 on endothelial
ETB receptor and, as a consequence, a release of
endothelial derived relaxing factor (EDRF) together
with prostacyclin (PGI2) and nitric oxide (NO)
(33ñ35). 
In CHF, an increase of ET-1 occurs, which cor-
relates with severity and advancement of CHF.
Initially, ET-1 greatly increases the contractility of
cardiac muscle and contributes to the maintenance
of vascular tone, thus acting with other neuroen-
docrine mechanisms as early compensatory
response. Moreover, ET-1, causing renal blood flow
decrease, leads to glomerular filtration rate deple-
tion and to sodium retention. However, in long-term
perspective, ET-1 causes cardiac remodelling, con-
tributing to cardiac contractility impairment and to
CHF acceleration. Apart from cardiac and vascular
effects, ET-1 is closely associated with RAAS. ET-
1 activates angiotensin converting enzyme, thus
leading to angiotensin II synthesis. On the other
hand, angiotensin II also causes increased endothe-
lin secretion. The synergistic action of angiotensin
II, aldosterone, endothelin and vasopressin results in
pathological cardiac remodelling, progressive
impairment of cardiac contractility and increase of
afterload, conditioned by vascular resistance eleva-
tion. Additionally, angiotensin II and endothelin are
proved to have proarrhythmic features, which also
favor further CHF progression. Taking into consid-
eration the mechanisms mentioned above, it should
be expected that ET-1 blockade (similarly to RAAS
inhibition) in CHF might be associated with benefi-
cial hemodynamic changes, protecting from further
heart failure exacerbation. There are attempts of
introduction in modern CHF pharmacotherapy new
agents acting through ET-1 blockade ñ endothelin
antagonists ñ ERAs (34, 36, 37). 
Currently investigated ERAs are selective ETA
single receptor or dual ETA/ETB blockers.
Considering some opposite effects originated from
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different receptor activation indicated above, one
should expected partly opposite pharmacological
results, depending on ERA selectivity. In accor-
dance with expectations, antagonistic impact on
ETA receptor leads to vasodilatation while selective
ETB blockade also results in vasodilatation and has
antiproliferative effect, but with some harmful
(endothelial EDRF, PGI2, NO decrease) influence.
Thus, some preclinical and clinical studies implicate
that selective ETB blockade may impair systemic
hemodynamic feature and there is no indications for
their introduction to CHF treatment. At present, the
common belief of superiority and rationale of dual
ETA/ETB or selective ETA endothelin receptor
antagonistsí administration exists (35). 
The adverse effects occurred during ERAs
treatment include headache, nausea, rhinitis, sinusi-
tis, dyspnea, chest pain and dose-related anemia.
Most of them are the result of non-specific, vasodi-
latatory ERAs feature. These agents also exert hepa-
totoxicity, probably because of their cholestatic
effect. ERAs also cause essential pharmacokinetic
interactions, effecting Cyp450 activity, which
metabolize many drugs (34). Preclinical studies con-
firmed that these agents are teratogenic, thus they
are contraindicated in pregnancy. In animal models,
persistent ductus arteriosus and craniofacial malfor-
mations were observed. The selected ERAs agents,
studied as a potentially useful in CHF treatment, are
presented in Table 2. 
Cytokines. Anticytokine therapy
Apart from essential role of neurohormones in
the CHF development, current studies are also
focused on the proinflammatory cytokines, such as
tumor necrosis factor alpha (TNF-α). This molecule
is produced as a prohormone, containing 233
aminoacids and then processed into a 157-amino
acids native form. The TNF-α synthesis is increased
in response to various stimuli: lipopolisaccharide,
viruses, fungal or parasitic agents, and interleukin-1.
On the other hand, TNF-α regulates the expression
of many various cytokines: interleukin-6, platelet
derived growth factor (PDGF), transforming growth
factor beta (TGF-β), platelet activating factor (PAF)
and other eicosanoids. Once released from cells,
TNF-α interacts with its receptors: a high affinity
TNFR-1 receptor and low affinity TNFR-2 one,
which differ each other with the signalling path-
ways. TNF-α exerts pleiotropic effects ñ it is co-
responsible for paracrine and autocrine regulation of
leukocytes and endothelial cells. It enhances chemo-
taxis, phagocytic and cytotoxic activity of
immunoreactive cells, promotes leucostasis by
inducing increased expression of intracellular adhe-
sion molecules (ICAMS) and endothelial leukocyte
adhesion molecules (ELAMS) at sides of inflamma-
tion. Thus TNF-α is a key factor of inflammatory
process. 
At higher concentrations, TNF-α exerts
endocrine effects, causing metabolic wasting,
microvascular coagulation, hypotension, heart con-
tractility impairment and fever. This cytokine also
modulates both tissue destruction and rebuilding by
activating of fibroblasts and mesynchymal cell pro-
liferation. It is also cytotoxic to endothelial cells and
induces the biosynthesis of collagenases, proteases,
reactive oxygen species and arachidonic acid
metabolites. TNF-α plays an important role in car-
diac remodelling and favors heart failure exacerba-
tion. Physiologically, high level of circulatory TNF-
α causes the TNFR extracellular protein liberation
into the circulation. The soluble receptors are able to
bind ligand and thus to inhibit the adverse effects of
high TNF-α level, thus serving as a clearance recep-
tor that can neutralize the activities of this cytokine.
In high amount TNF-α level, this clearance mecha-
nism is inefficient (38). 
It was also discovered, that TNF-α also partic-
ipates in CHF pathogenesis. The level of this
cytokine is elevated, especially in patients with end
stage of heart failure and cachexia, potentiating the
negative inotropic effect. It seems that TNF-α effec-
tively uncouples the β-adrenergic receptors from
adenylyl cyclase, activates metalloproteinases and
inhibits the expression of inhibitors of metallopro-
teinases, leading to extracellular matrix remodelling.
TNF-α also provokes a hypertrophic growth
response in cardiac myocytes, which may be a
response to hemodynamic stress (38ñ42). 
Based on the findings, the concept of anticy-
tokine pharmacological TNF-α blockade in CHF
raised. It was observed that β-adrenergic agonists
may inhibit TNF-α production, probably by elevat-
ing intracellular cAMP level. Phospodiesterase
inhibitors also can diminish TNF-α secretion.
Pentoxyfilline demonstrated beneficial effect in
failed heart which was associated with decreasing
TNF-α level. It was also found that adenosine is a
potent TNF-α blocker. The next therapeutical strate-
gy is based on the passive immunization mecha-
nisms. Monoclonal antibodies against TNF-α (e.g.,
Infliximab) were effective in ameliorating the effects
of sepsis, cancer and inflammatory bowel diseases.
There is a question if administration of anty-TNF-α
Ig in CHF also results in therapeutic efficiency. The
next therapeutic option of myocardial TNF-α sup-
pression is the use of recombinant TNF-α soluble
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receptor (Etanercept). This agent has already been
approved by FDA in rheumatoid arthritis treatment.
The clinical trials estimating rationale for Etanercept
using in CHF are still ongoing, however, the prelim-
inary results suggest that this agent is well-tolerated
and causes decreasing of circulatory TNF-α of about
70% for at least 14 days, results in clinical CHF
course and quality of life improvement (38, 43). 
Conclusions
Over the past decades, the approach to CHF
treatment has completely changed. In the past, CHF
was regarded to be a clinical entity characterized
mainly by poor contracting heart. Nowadays, CHF
is understood as a complex autonomic ñ neuroen-
docrine disorder. Thus, the previous pharmacologi-
cal guidelines based on inotropic agents, diuretics
and vasodilatators have been re-evaluated. Lately
investigators interest is focused on CHF neurohor-
monal mechanisms (VRA, ERA, NEPI, VPI, anti-
TNF-α). However, results of clinical trials are still
limited and scrappy. Further studies are required to
confirm additional areas of modern CHF treatment.
Introduction of new classes of medicaments, related
to autonomic and neuroendocrine pathomech-
anisms, seems possible.
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